New Combination Strategy to Overcome Estrogen Receptor Resistance

Global clinical research organization MEDSIR and Stemline Therapeutics, a subsidiary of the Menarini Group, have launched a joint study targeting patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. The Phase 3 ADELA (NCT06382948) trial focuses on patients whose disease has progressed after endocrine therapy and CDK4/6 inhibitor treatment and who carry the key ESR1 gene mutation. ESR1 mutations cause structural changes in the estrogen receptor, leading to strong resistance to standard therapies, making the development of new treatment options urgent. The research team expects a synergistic effect from combining Elacestrant (brand name 'Orserdu'), a selective estrogen receptor degrader (SERD), with Everolimus (brand name 'Afinitor'), an mTOR inhibitor, to simultaneously block resistance mechanisms.

Blocking Bypass Pathways through Mechanistic Interaction

The scientific rationale for this trial is based on the close interaction (crosstalk) between the estrogen receptor (ER) signaling pathway and the PI3K/AKT/mTOR cell proliferation pathway. By exploiting the tumor cells' tendency to activate the mTOR pathway to bypass estrogen blockage, the combination of Elacestrant, which directly degrades the receptor, and Everolimus, which blocks downstream signaling, is designed to preemptively block the common bypass resistance pathways observed with monotherapies. This strategy aims to significantly improve survival rates for patients with refractory breast cancer who have failed standard treatments. The trial is being conducted based on promising early efficacy data from the Phase 2 ELEVATE study, generating high expectations in the clinical community.

Combination of Regulated Assets and Market Entry Strategy

Both drugs used in the trial have already received regulatory approval, offering a significant advantage in terms of reduced commercial risk. Elacestrant was first approved by the U.S. Food and Drug Administration (FDA) on January 27, 2023, and by the European Medicines Agency (EMA) on September 15, 2023, for the treatment of ESR1-mutant metastatic breast cancer. Everolimus was approved in 2012 and is widely used. By combining two drugs with established safety profiles, the uncertainty of toxicity associated with new drug development is minimized, and rapid market adoption is expected in the event of clinical success. This aligns with Menarini Group's strategy to maximize pipeline value through rapid commercialization.

Expectation of Standard-of-Care Transition through PFS Improvement

The primary endpoint of the trial is investigator-assessed progression-free survival (PFS), which will clearly compare the efficacy of the two drugs. Patients will be randomly assigned in a 1:1 ratio to either the combination therapy group (Arm A) or the monotherapy group (Arm B) for comparative analysis. If this combination therapy demonstrates statistically significant PFS extension compared to monotherapy, it is likely to quickly become a new standard of care in the second-line treatment setting following CDK4/6 inhibitor failure. This could provide patients with tangible clinical benefits by delaying the need for cytotoxic chemotherapy and preserving quality of life.